Benzoic acid derivatives represented by the general formula (I), nontoxic salts thereof, a process for producing the same and drugs containing the same as the active ingredient; (I) wherein A, B, R?6 and R7¿ represent each a carbon ring, a heterocycle, etc.; R1 represents hydroxy, etc.; R?2, R3 and R4¿ represent each alkyl, etc.; R5, D and E represent each alkylene, etc.; and G represents oxygen, etc. Because of strongly binding particularly to the subtype EP¿4? of PGE2 receptor, the compounds represented by the general formula (I) are expected as useful in preventing and/or treating bone diseases, cancer, systemic granuloma, immunologic diseases, allergy, atopy, asthma, alveolar abscess, gingivitis, peridontosis, nerve cell death, Alzheimer's disease, lung disorder, liver disorder, acute hepatitis, nephritis, renal insufficiency, myocardial ischemia, Kawasaki's disease, burn, ulcerative colitis, Crohn's disease, multiple failure, etc. and diseases in association with sleep failure or platelet aggregation.